RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2020

Mar 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2020-03-17

Reporting Person: Foley Todd (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-17	Common Stock	S	9653	$15.12	Disposed	2383844	Indirect
2020-03-18	Common Stock	S	12781	$15.14	Disposed	2371063	Indirect
2020-03-19	Common Stock	S	8200	$15.07	Disposed	2362863	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The shares were sold as follows: 9,292 by MPM BioVentures V, L.P. ("BV V") and 361 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.41. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Shares are held as follows: 2,294,700 by BV V and 89,144 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: Shares were sold as follows: 12,296 by BV V and 485 by AM BV5.

F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.61. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: Shares are held as follows: 2,282,404 by BV V and 88,659 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F8: Shares were sold as follows: 7,889 by BV V and 311 by AM BV5.

F9: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.47. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10: Shares are held as follows: 2,274,575 by BV V and 88,348 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.